148 related articles for article (PubMed ID: 16986707)
1. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
2. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
3. Analysis of the progression of JAK2 V617F positive myeloproliferative neoplasms by single-nucleotide polymorphism array does not reveal a strong chromosomal instability.
Knoops L; Amyere M; Selleslag D; van Hees J; Girardot M; Michaux L
Cancer Genet Cytogenet; 2009 Jul; 192(2):102-4. PubMed ID: 19596266
[No Abstract] [Full Text] [Related]
4. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
5. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL; Pardanani A; Tefferi A; Gilliland DG
Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
[TBL] [Abstract][Full Text] [Related]
6. [JAK2 mutation can be used in diagnosis of myeloproliferative diseases].
Zhu P
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2243-5. PubMed ID: 17064566
[No Abstract] [Full Text] [Related]
7. [Myeloproliferative diseases caused by Jak2 gene mutation].
Shide K
Rinsho Ketsueki; 2007 Mar; 48(3):183-7. PubMed ID: 17441474
[No Abstract] [Full Text] [Related]
8. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
[No Abstract] [Full Text] [Related]
9. Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.
Skoda R
Eur J Haematol Suppl; 2007 Oct; (68):5-8. PubMed ID: 17727557
[No Abstract] [Full Text] [Related]
10. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
Go RS
Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
[No Abstract] [Full Text] [Related]
11. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
[No Abstract] [Full Text] [Related]
13. A novel JAK2 splicing mutation in neonatal myeloproliferative disorder accompanying congenital anomalies.
Ohnishi H; Hosoi K; Yoshino H; Sugiura M; Matsushima S; Watanabe T; Bessho F
Br J Haematol; 2009 Jun; 145(5):676-8. PubMed ID: 19344419
[No Abstract] [Full Text] [Related]
14. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
15. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
[TBL] [Abstract][Full Text] [Related]
16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
17. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
18. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
19. JAK2 (V617F) mutation in healthy individuals.
Passamonti F; Rumi E; Pietra D; Lazzarino M; Cazzola M
Br J Haematol; 2007 Feb; 136(4):678-9. PubMed ID: 17223913
[No Abstract] [Full Text] [Related]
20. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
Campbell P
Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
